Cargando…

From first to second wave: follow-up of the prospective COVID-19 cohort (KoCo19) in Munich (Germany)

BACKGROUND: In the 2nd year of the COVID-19 pandemic, knowledge about the dynamics of the infection in the general population is still limited. Such information is essential for health planners, as many of those infected show no or only mild symptoms and thus, escape the surveillance system. We ther...

Descripción completa

Detalles Bibliográficos
Autores principales: Radon, Katja, Bakuli, Abhishek, Pütz, Peter, Le Gleut, Ronan, Guggenbuehl Noller, Jessica Michelle, Olbrich, Laura, Saathoff, Elmar, Garí, Mercè, Schälte, Yannik, Frahnow, Turid, Wölfel, Roman, Pritsch, Michael, Rothe, Camilla, Pletschette, Michel, Rubio-Acero, Raquel, Beyerl, Jessica, Metaxa, Dafni, Forster, Felix, Thiel, Verena, Castelletti, Noemi, Rieß, Friedrich, Diefenbach, Maximilian N., Fröschl, Günter, Bruger, Jan, Winter, Simon, Frese, Jonathan, Puchinger, Kerstin, Brand, Isabel, Kroidl, Inge, Wieser, Andreas, Hoelscher, Michael, Hasenauer, Jan, Fuchs, Christiane
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8423599/
https://www.ncbi.nlm.nih.gov/pubmed/34493217
http://dx.doi.org/10.1186/s12879-021-06589-4
_version_ 1783749498189643776
author Radon, Katja
Bakuli, Abhishek
Pütz, Peter
Le Gleut, Ronan
Guggenbuehl Noller, Jessica Michelle
Olbrich, Laura
Saathoff, Elmar
Garí, Mercè
Schälte, Yannik
Frahnow, Turid
Wölfel, Roman
Pritsch, Michael
Rothe, Camilla
Pletschette, Michel
Rubio-Acero, Raquel
Beyerl, Jessica
Metaxa, Dafni
Forster, Felix
Thiel, Verena
Castelletti, Noemi
Rieß, Friedrich
Diefenbach, Maximilian N.
Fröschl, Günter
Bruger, Jan
Winter, Simon
Frese, Jonathan
Puchinger, Kerstin
Brand, Isabel
Kroidl, Inge
Wieser, Andreas
Hoelscher, Michael
Hasenauer, Jan
Fuchs, Christiane
author_facet Radon, Katja
Bakuli, Abhishek
Pütz, Peter
Le Gleut, Ronan
Guggenbuehl Noller, Jessica Michelle
Olbrich, Laura
Saathoff, Elmar
Garí, Mercè
Schälte, Yannik
Frahnow, Turid
Wölfel, Roman
Pritsch, Michael
Rothe, Camilla
Pletschette, Michel
Rubio-Acero, Raquel
Beyerl, Jessica
Metaxa, Dafni
Forster, Felix
Thiel, Verena
Castelletti, Noemi
Rieß, Friedrich
Diefenbach, Maximilian N.
Fröschl, Günter
Bruger, Jan
Winter, Simon
Frese, Jonathan
Puchinger, Kerstin
Brand, Isabel
Kroidl, Inge
Wieser, Andreas
Hoelscher, Michael
Hasenauer, Jan
Fuchs, Christiane
author_sort Radon, Katja
collection PubMed
description BACKGROUND: In the 2nd year of the COVID-19 pandemic, knowledge about the dynamics of the infection in the general population is still limited. Such information is essential for health planners, as many of those infected show no or only mild symptoms and thus, escape the surveillance system. We therefore aimed to describe the course of the pandemic in the Munich general population living in private households from April 2020 to January 2021. METHODS: The KoCo19 baseline study took place from April to June 2020 including 5313 participants (age 14 years and above). From November 2020 to January 2021, we could again measure SARS-CoV-2 antibody status in 4433 of the baseline participants (response 83%). Participants were offered a self-sampling kit to take a capillary blood sample (dry blood spot; DBS). Blood was analysed using the Elecsys® Anti-SARS-CoV-2 assay (Roche). Questionnaire information on socio-demographics and potential risk factors assessed at baseline was available for all participants. In addition, follow-up information on health-risk taking behaviour and number of personal contacts outside the household (N = 2768) as well as leisure time activities (N = 1263) were collected in summer 2020. RESULTS: Weighted and adjusted (for specificity and sensitivity) SARS-CoV-2 sero-prevalence at follow-up was 3.6% (95% CI 2.9–4.3%) as compared to 1.8% (95% CI 1.3–3.4%) at baseline. 91% of those tested positive at baseline were also antibody-positive at follow-up. While sero-prevalence increased from early November 2020 to January 2021, no indication of geospatial clustering across the city of Munich was found, although cases clustered within households. Taking baseline result and time to follow-up into account, men and participants in the age group 20–34 years were at the highest risk of sero-positivity. In the sensitivity analyses, differences in health-risk taking behaviour, number of personal contacts and leisure time activities partly explained these differences. CONCLUSION: The number of citizens in Munich with SARS-CoV-2 antibodies was still below 5% during the 2nd wave of the pandemic. Antibodies remained present in the majority of SARS-CoV-2 sero-positive baseline participants. Besides age and sex, potentially confounded by differences in behaviour, no major risk factors could be identified. Non-pharmaceutical public health measures are thus still important. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12879-021-06589-4.
format Online
Article
Text
id pubmed-8423599
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-84235992021-09-08 From first to second wave: follow-up of the prospective COVID-19 cohort (KoCo19) in Munich (Germany) Radon, Katja Bakuli, Abhishek Pütz, Peter Le Gleut, Ronan Guggenbuehl Noller, Jessica Michelle Olbrich, Laura Saathoff, Elmar Garí, Mercè Schälte, Yannik Frahnow, Turid Wölfel, Roman Pritsch, Michael Rothe, Camilla Pletschette, Michel Rubio-Acero, Raquel Beyerl, Jessica Metaxa, Dafni Forster, Felix Thiel, Verena Castelletti, Noemi Rieß, Friedrich Diefenbach, Maximilian N. Fröschl, Günter Bruger, Jan Winter, Simon Frese, Jonathan Puchinger, Kerstin Brand, Isabel Kroidl, Inge Wieser, Andreas Hoelscher, Michael Hasenauer, Jan Fuchs, Christiane BMC Infect Dis Research Article BACKGROUND: In the 2nd year of the COVID-19 pandemic, knowledge about the dynamics of the infection in the general population is still limited. Such information is essential for health planners, as many of those infected show no or only mild symptoms and thus, escape the surveillance system. We therefore aimed to describe the course of the pandemic in the Munich general population living in private households from April 2020 to January 2021. METHODS: The KoCo19 baseline study took place from April to June 2020 including 5313 participants (age 14 years and above). From November 2020 to January 2021, we could again measure SARS-CoV-2 antibody status in 4433 of the baseline participants (response 83%). Participants were offered a self-sampling kit to take a capillary blood sample (dry blood spot; DBS). Blood was analysed using the Elecsys® Anti-SARS-CoV-2 assay (Roche). Questionnaire information on socio-demographics and potential risk factors assessed at baseline was available for all participants. In addition, follow-up information on health-risk taking behaviour and number of personal contacts outside the household (N = 2768) as well as leisure time activities (N = 1263) were collected in summer 2020. RESULTS: Weighted and adjusted (for specificity and sensitivity) SARS-CoV-2 sero-prevalence at follow-up was 3.6% (95% CI 2.9–4.3%) as compared to 1.8% (95% CI 1.3–3.4%) at baseline. 91% of those tested positive at baseline were also antibody-positive at follow-up. While sero-prevalence increased from early November 2020 to January 2021, no indication of geospatial clustering across the city of Munich was found, although cases clustered within households. Taking baseline result and time to follow-up into account, men and participants in the age group 20–34 years were at the highest risk of sero-positivity. In the sensitivity analyses, differences in health-risk taking behaviour, number of personal contacts and leisure time activities partly explained these differences. CONCLUSION: The number of citizens in Munich with SARS-CoV-2 antibodies was still below 5% during the 2nd wave of the pandemic. Antibodies remained present in the majority of SARS-CoV-2 sero-positive baseline participants. Besides age and sex, potentially confounded by differences in behaviour, no major risk factors could be identified. Non-pharmaceutical public health measures are thus still important. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12879-021-06589-4. BioMed Central 2021-09-08 /pmc/articles/PMC8423599/ /pubmed/34493217 http://dx.doi.org/10.1186/s12879-021-06589-4 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Radon, Katja
Bakuli, Abhishek
Pütz, Peter
Le Gleut, Ronan
Guggenbuehl Noller, Jessica Michelle
Olbrich, Laura
Saathoff, Elmar
Garí, Mercè
Schälte, Yannik
Frahnow, Turid
Wölfel, Roman
Pritsch, Michael
Rothe, Camilla
Pletschette, Michel
Rubio-Acero, Raquel
Beyerl, Jessica
Metaxa, Dafni
Forster, Felix
Thiel, Verena
Castelletti, Noemi
Rieß, Friedrich
Diefenbach, Maximilian N.
Fröschl, Günter
Bruger, Jan
Winter, Simon
Frese, Jonathan
Puchinger, Kerstin
Brand, Isabel
Kroidl, Inge
Wieser, Andreas
Hoelscher, Michael
Hasenauer, Jan
Fuchs, Christiane
From first to second wave: follow-up of the prospective COVID-19 cohort (KoCo19) in Munich (Germany)
title From first to second wave: follow-up of the prospective COVID-19 cohort (KoCo19) in Munich (Germany)
title_full From first to second wave: follow-up of the prospective COVID-19 cohort (KoCo19) in Munich (Germany)
title_fullStr From first to second wave: follow-up of the prospective COVID-19 cohort (KoCo19) in Munich (Germany)
title_full_unstemmed From first to second wave: follow-up of the prospective COVID-19 cohort (KoCo19) in Munich (Germany)
title_short From first to second wave: follow-up of the prospective COVID-19 cohort (KoCo19) in Munich (Germany)
title_sort from first to second wave: follow-up of the prospective covid-19 cohort (koco19) in munich (germany)
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8423599/
https://www.ncbi.nlm.nih.gov/pubmed/34493217
http://dx.doi.org/10.1186/s12879-021-06589-4
work_keys_str_mv AT radonkatja fromfirsttosecondwavefollowupoftheprospectivecovid19cohortkoco19inmunichgermany
AT bakuliabhishek fromfirsttosecondwavefollowupoftheprospectivecovid19cohortkoco19inmunichgermany
AT putzpeter fromfirsttosecondwavefollowupoftheprospectivecovid19cohortkoco19inmunichgermany
AT legleutronan fromfirsttosecondwavefollowupoftheprospectivecovid19cohortkoco19inmunichgermany
AT guggenbuehlnollerjessicamichelle fromfirsttosecondwavefollowupoftheprospectivecovid19cohortkoco19inmunichgermany
AT olbrichlaura fromfirsttosecondwavefollowupoftheprospectivecovid19cohortkoco19inmunichgermany
AT saathoffelmar fromfirsttosecondwavefollowupoftheprospectivecovid19cohortkoco19inmunichgermany
AT garimerce fromfirsttosecondwavefollowupoftheprospectivecovid19cohortkoco19inmunichgermany
AT schalteyannik fromfirsttosecondwavefollowupoftheprospectivecovid19cohortkoco19inmunichgermany
AT frahnowturid fromfirsttosecondwavefollowupoftheprospectivecovid19cohortkoco19inmunichgermany
AT wolfelroman fromfirsttosecondwavefollowupoftheprospectivecovid19cohortkoco19inmunichgermany
AT pritschmichael fromfirsttosecondwavefollowupoftheprospectivecovid19cohortkoco19inmunichgermany
AT rothecamilla fromfirsttosecondwavefollowupoftheprospectivecovid19cohortkoco19inmunichgermany
AT pletschettemichel fromfirsttosecondwavefollowupoftheprospectivecovid19cohortkoco19inmunichgermany
AT rubioaceroraquel fromfirsttosecondwavefollowupoftheprospectivecovid19cohortkoco19inmunichgermany
AT beyerljessica fromfirsttosecondwavefollowupoftheprospectivecovid19cohortkoco19inmunichgermany
AT metaxadafni fromfirsttosecondwavefollowupoftheprospectivecovid19cohortkoco19inmunichgermany
AT forsterfelix fromfirsttosecondwavefollowupoftheprospectivecovid19cohortkoco19inmunichgermany
AT thielverena fromfirsttosecondwavefollowupoftheprospectivecovid19cohortkoco19inmunichgermany
AT castellettinoemi fromfirsttosecondwavefollowupoftheprospectivecovid19cohortkoco19inmunichgermany
AT rießfriedrich fromfirsttosecondwavefollowupoftheprospectivecovid19cohortkoco19inmunichgermany
AT diefenbachmaximiliann fromfirsttosecondwavefollowupoftheprospectivecovid19cohortkoco19inmunichgermany
AT froschlgunter fromfirsttosecondwavefollowupoftheprospectivecovid19cohortkoco19inmunichgermany
AT brugerjan fromfirsttosecondwavefollowupoftheprospectivecovid19cohortkoco19inmunichgermany
AT wintersimon fromfirsttosecondwavefollowupoftheprospectivecovid19cohortkoco19inmunichgermany
AT fresejonathan fromfirsttosecondwavefollowupoftheprospectivecovid19cohortkoco19inmunichgermany
AT puchingerkerstin fromfirsttosecondwavefollowupoftheprospectivecovid19cohortkoco19inmunichgermany
AT brandisabel fromfirsttosecondwavefollowupoftheprospectivecovid19cohortkoco19inmunichgermany
AT kroidlinge fromfirsttosecondwavefollowupoftheprospectivecovid19cohortkoco19inmunichgermany
AT wieserandreas fromfirsttosecondwavefollowupoftheprospectivecovid19cohortkoco19inmunichgermany
AT hoelschermichael fromfirsttosecondwavefollowupoftheprospectivecovid19cohortkoco19inmunichgermany
AT hasenauerjan fromfirsttosecondwavefollowupoftheprospectivecovid19cohortkoco19inmunichgermany
AT fuchschristiane fromfirsttosecondwavefollowupoftheprospectivecovid19cohortkoco19inmunichgermany
AT fromfirsttosecondwavefollowupoftheprospectivecovid19cohortkoco19inmunichgermany